semaj83/ctmatch_classification huggingface dataset:
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Pregnancy Related Immunization; Infection Pertussis Pregnant and not yet having received pertussis vaccination Willing and able to comply with study procedures and provide informed consent Documentation of a 20-week anomaly scan with no life limiting congenital anomalies identified  Age less than 16 years Confirmed or suspected pertussis in previous five years Known diagnosis of immune deficiency Receiving immunosuppressive medication within six months of enrolment in the study (this does not inhaled or topical steroids) In the opinion of the investigator is unlikely to complete follow up
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 1.0-24.0,  B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia B-ALL and MPAL patients must be enrolled on APEC14B1 and consented to studies (Part A) prior to treatment and enrollment on AALL1732. Note that central confirmation of MPAL diagnosis must occur within 7 business days after enrollment for MPAL patients. If not performed within this time frame, patients will be taken off protocol APEC14B1 is not a requirement for B-LLy patients but for institutional compliance every patient should be offered participation in APEC14B1. B-LLy patients may directly enroll on AALL1732 White blood cell count (WBC) for patients with B-ALL (within 7 days prior to the start of protocol-directed systemic therapy) Age 1-9.99 years: WBC >= 50,000/uL Age 10-24.99 years: Any WBC Age 1-9.99 years: WBC < 50,000/uL with Testicular leukemia CNS leukemia (CNS3) Steroid pretreatment White blood cell count (WBC) for patients with MPAL (within 7 days prior to the start of protocol-directed systemic therapy)  Patients with Down syndrome are not eligible (patients with Down syndrome and B-ALL are eligible for AALL1731, regardless of NCI risk group) With the exception of steroid pretreatment or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for the current diagnosis of B-ALL, MPAL, or B-LLy or for any cancer diagnosed prior to initiation of protocol therapy on AALL1732 Patients who have received > 72 hours of hydroxyurea within one week prior to start of systemic protocol therapy Patients with B-ALL or MPAL who do not have sufficient diagnostic bone marrow submitted for APEC14B1 testing and who do not have a peripheral blood sample submitted containing > 1,000/uL circulating leukemia cells Patients with acute undifferentiated leukemia (AUL) are not eligible For Murphy stage III/IV B-LLy patients, or stage I/II patients with steroid pretreatment, the following additional apply T-lymphoblastic lymphoma Morphologically unclassifiable lymphoma Absence of both B-cell and T-cell phenotype markers in a case submitted as lymphoblastic lymphoma
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anxiety Depression Posttraumatic Stress Disorder Psychological Distress Adults of 18 years or above Syrian under temporary protection status Arabic-speaking Elevated levels of psychological distress (K10 >15) and reduced psychosocial functioning (WHODAS 2.0 >16)  Acute medical conditions Imminent suicide risk or expressed acute needs/protection risks (e.g., a young woman who expresses that she is at acute risk of being assaulted or killed) Severe mental disorder (psychotic disorders, substance-dependence) Severe cognitive impairment (e.g., severe intellectual disability or dementia)
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Trismus Head and Neck Cancer Epidermoid carcinoma of the buccal cavity, oropharynx or cavum Radiotherapy (≥ 54Gy in the oropharynx) and concomitant chemotherapy (including targeted therapies) with or without surgery Patients ≥ 18 years old, understanding French Patients who gave their informed consent prior to the study  Disease and/or trauma with an effect on jaw mobility with permanent trismus Psychiatric non-stabilized comorbidity Lack of the median and lateral incisors Metastatic patient Legal inability or limited legal capacity. Medical or psychological conditions inducing incapacity of the subject to complete the study or give his/her consent
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Breast Cancer Contraceptive Usage Sexually Transmitted Diseases -Scheduled to leave jail within 3 days  not actively intoxicated not show severe psychological distress
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 8.0-15.0,  Reproductive Physiological Processes Pediatrics Adolescent Health Adolescent Developement Part 1-Pre-menarche monitoring (holding pattern) Age 8-14.5 years old Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile Some breast development Pre-menarche  Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills) Planning to move more than 60 miles from the CRU within the next 2 years Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder Excessive exercise (defined as running >20 miles per week or its equivalent) Pregnancy Part 2 Post-menarche cycle tracking Age at menarche 10-14.5 years old Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile Approximately less than or equal to 6 months post-menarchal (will typically have completed 4 or fewer menstrual cycles) Biochemical normal thyroid hormone, prolactin, and testosterone levels
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Viral Infection Patients has to have received a prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow, single/double cord blood or PBSC 2. Cells administered as: 1. Treatment of relapsed or persistent reactivation or infection for EBV, CMV, adenovirus, and/or BK virus despite standard therapy. Multiple infections are eligible to enroll. 2. Early treatment for single or multiple infections with EBV, CMV, adenovirus, and/or BK virus following treatment failure or in patients who are unable to tolerate standard therapy 3. Treatment of JC virus infection 3. Steroids less than or equal to 1.0 mg/kg/day methylprednisolone (or equivalent) 4. Hgb ≥ 7.0 gm/dl 5. Available VSTs must be partially HLA matched and verified 6. Negative pregnancy test (if female of childbearing potential after reduced intensity conditioning) 7. Patient or parent/guardian capable of providing informed consent  Received ATG (anti-thymocyte globulin), Campath or other T cell immunosuppressive monoclonal antibodies in the last 28 days. 2. Patients with other uncontrolled infections 3. Patients who are less than 28 days removed from their allogeneic hematopoietic stem cell transplant or who have received donor lymphocyte infusions (DLI) within 28 days. 4. Evidence of GVHD >= grade 2 5. Active and uncontrolled relapse of malignancy 6. Requirement for FiO2 (fraction of inspired oxygen) > 50% oxygen to maintain arterial oxygen saturation > 90%.Note: patients requiring oxygen at FiO2<=50% to maintain arterial oxygen saturation >90% are eligible to receive VSTs if the reason for this oxygen requirement is believed attributable to the virus being treated
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 1.0-1.5,  Microbiota Complementary Food Nutrition Parent(s) willing to sign consent form; the informed consent document will explicitly request permission to use the collected fecal samples for future studies, including but not limited to culturing component bacterial strains Child age 12-18 months WLZ between <-2 and -3 without bilateral pedal edema at the time of randomization Parent(s) willing to bring the child to the feeding centre twice daily for 4 weeks for nutritional therapy, once daily for next 4 weeks and administer the feeds provided by study staff once daily at home for 4 weeks and twice daily for next 4 weeks  Medical conditions: Children with tuberculosis (diagnosis based on WHO 2014 guidelines which have been incorporated in the national TB control guidelines of Bangladesh). The guidelines depend upon the following five diagnostic principles (three out of five should be positive): 1. Specific symptoms of TB, 2. Specific signs, 3. Chest X-ray, 4. Mantoux test, and 5. History of contact,[9] or any congenital/acquired disorder affecting growth i.e. known case of trisomy-21 or cerebral palsy; children on an diet for the treatment of persistent diarrhea; having known history of soy, peanut or milk protein allergy Severe anemia (<8mg/dl), will be assessed by Hemocue (Model no. Hemocue Hb 301) Failure to obtain informed written consent from parents or caretakers
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Influenza A Healthy Male or Female age 18 to < 65 years Body mass index (BMI) of 18.0 kg/m^2 to 35.0kg/m^2  Any prior or planned influenza vaccination for the upcoming flu season Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation History of influenza-like illness or confirmed influenza infection within 3 months prior to randomization Fever-like illness within 5 days of randomization History or clinical evidence of conditions considered high risk for developing influenza-related complications
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.164-0.244,  Vaccination subjects aged from 60 days to 89 days old at the date of recruitment with informed consent signed by parent(s) or guardians parent(s) or guardians are able to attend all planned clinical appointments and obey and follow all study instructions subjects did not receive any vaccines within 14 days axillary temperature ≤37.0℃  allergic to any ingredient of vaccine or with allergy history to any vaccine acute febrile disease or infectious disease serious chronic diseases any other factor that makes the investigator determines the subject is unsuitable for this study
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.25-0.25,  Vaccination subjects aged 3 months old at the date of recruitment with informed consent signed by parent(s) or guardians parent(s) or guardians are able to attend all planned clinical appointments and obey and follow all study instructions subjects have not been vaccinated with IPV vaccine, OPV vaccine, DTP vaccine and related vaccines  subject who has a medical history with Hypersensitiveness, eclampsia, epilepsy, cerebropathia and neurological illness allergic to any ingredient of vaccine or with allergy history to any vaccine subjects with immunodeficency or suspected impairment of immunologic function (e.g. caused by HIV), or subjects are in the process of immunosuppressor therapy(Taking orally injecting of steroid hormone) administration of immunoglobulins within 30 days prior to this study acute febrile disease(temperature ≥ 37.0°C) or infectious disease have a clearly diagnosed history of thrombocytopenia or other coagulopathy, may cause contraindications for subcutaneous injection any serious chronic illness, acute infectious diseases, or respiratory diseases severe cardiovascular disease, liver and kidney diseases or diabetes mellitus with complications any kind of infectious, purulent, or allergic skin diseases any other factor that makes the investigator determines the subject is unsuitable for this study
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.25-0.25,  Vaccination subjects aged 3 months old at the date of recruitment with informed consent signed by parent(s) or guardians parent(s) or guardians are able to attend all planned clinical appointments and obey and follow all study instructions subjects have not been vaccinated with IPV vaccine, OPV vaccine, DTP vaccine and related vaccines  subject who has a medical history with hypersensitiveness, eclampsia, epilepsy, cerebropathy and neurological illness allergic to any ingredient of vaccine or with allergy history to any vaccine subjects with immunodeficiency or suspected impairment of immunologic function (e.g. caused by HIV), or subjects are in the process of immunosuppressor therapy(Taking orally injecting of steroid hormone) administration of immunoglobulins within 30 days prior to this study acute febrile disease(temperature ≥ 37.0°C) or infectious disease have a clearly diagnosed history of thrombocytopenia or other coagulopathy may cause contraindications for subcutaneous injection any serious chronic illness, acute infectious diseases, or respiratory diseases severe cardiovascular disease, liver and kidney diseases or diabetes mellitus with complications any kind of infectious, purulent, or allergic skin diseases
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Steroid Dependent Crohn's Disease Patients with biopsy confirmed, active, steroid dependent CD, without nutrient absorbance problems (Definition of steroid dependency: CD being treated with at least 5 mg/day steroids for the last 3 months; an attempt to reduce the dose induces flare of disease as determined by physician assessment). 2. Age ≥18 years 3. Steroid treatment of at least 3 months and stable steroid dose for at least 2 weeks .If thiopurines and/or biologics are also being administered, then must be administered at stable dose(s) for at least 3 months. 4. Patients will undergo an ECG and QT parameters will be measured for further analysis. 5. Female subjects who are postmenopausal (absence of menses for ≥ 2 years confirmed by a follicle stimulating hormone test), or who are surgically sterilized may be enrolled. Similarly, women of childbearing potential who had a negative pregnancy test at screening, who are willing to use two medically acceptable methods of contraception for the duration of the study as well as for at least three months after cessation of CBD treatment and who are willing to undergo pregnancy testing according to the study protocol may be enrolled. 6. Female subjects who are not breast-feeding and who have no intention to breast-feed during the term of the trial and for at least three months after cessation of CBD treatment may be enrolled. 7. Subject able to provide written informed consent  Viral Hepatitis (HAV, HBV, HCV) 2. HIV 3. Serious psychiatric or psychological disorders 4. Active consumption of illicit drugs including cannabis or derivatives for at least 3 months prior to the study 5. Patients with short bowel syndrome, symptomatic stricture, abscess, recent history (within the previous 3 months) of abdominal surgery, nutrient absorbance problems 6. Patients whose disease is inaccessible by endoscopy 7. Patients with significant cardiac, respiratory or active malignance disease (except Basel Cell Carcinoma) comorbidities. 8. Any uncontrolled infection at time of registration 9. Renal comorbidity: eGFR < 30 mL/min/1.73 m2 (note: CKD Grade 4 is defined as eGFR 15-29 mL/min/1.73 m2) 10. Patient who is taking immunomodulatory medications for other indication 11. Women of child-bearing potential who intend to become pregnant or who are pregnant or breastfeeding -
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Myeloid Leukemia Adult patients (age ≥ 18 years) with de novo or treatment-related AML, eligible and fit for SCT treatment according to national/international guidelines One or more potential haplo-identical related donor(s) AND five or more potential 6/6 HLA-A, -B, and -DRB1 antigen matched unrelated donors identified before randomization Karnofsky Performance Status ≥ 70% at randomization Signed informed consent Patient willing and able to comply with protocol requirements  Patients with a suitable HLA-identical sibling donor Patients with < 5 potential HLA-A, -B, and -DRB1 antigen matched URDs available Patients with no potential haplo-identical related donor available Patients scheduled for/receiving cord blood stem cell transplantation Prior allogeneic SCT using any hematopoietic stem cell source Patients seropositive for HIV Pregnancy (positive β-HCG test) within 4 weeks of study entry Cardiac ejection fraction < 45% Karnofsky Performance Status < 70% at time of randomization The presence of any psychological, family-related, social, and/or geographical condition potentially jeopardizing compliance with the study protocol and follow-up schedule